search
Back to results

Hemangioma Associated With High Rates of Morbidity

Primary Purpose

Hemangioma

Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
MRI
MRI of head and neck
Dermatological Examination
Cardiac examination
Abdominal ultrasound
Sponsored by
Medical College of Wisconsin
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional screening trial for Hemangioma focused on measuring Hemangioma, PHACE, Lumbosacral hemangioma, Occult Spinal Dysraphism

Eligibility Criteria

undefined - 18 Years (Child, Adult)All SexesDoes not accept healthy volunteers

Segmental Facial Hemangioma

Inclusion criteria:

  • Infants less than 1 year of age
  • Hemangiomas of the head /facial area measuring 22cm2 or greater.

Exclusion criteria:

  • Children greater than 1 year of age.
  • Children with segmental hemangiomas present in locations other than the head.
  • Children presenting with localized (focal) or indeterminate hemangiomas in any location.
  • Children with other vascular tumors (such as tufted angioma, Kaposiform hemangioendothelioma, non-involuting congenital hemangioma or rapidly-involuting congenital hemangioma) or vascular malformations.

Lumbosacral Hemangioma

Inclusion criteria:

  • Individuals less than 18 years of age.
  • Hemangioma, hemangioma precursor, or definitive residual hemangioma larger then 2.5 cm in diameter, overlying the midline lumbar spine or sacral spine in which any portion of the hemangioma is located over the midline.

Exclusion Criteria:

  • Excluding perirectal hemangiomas that do not extend onto the sacral spine.
  • Excluding perineal hemangiomas that do extend to overlay the sacral spine.

Sites / Locations

  • Beth Drolet, MD

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Other

Other

Other

Arm Label

Facial Hemangioma

Lumbosacral Hemangioma

Multiple Hemangiomas

Arm Description

Patients with large facial hemangioma.

Patients with lumbosacral hemangioma.

patients with multiple hemangiomas (>5)

Outcomes

Primary Outcome Measures

MRI/MRA of Head/Neck/Chest.
Clinical Diagnosis of PHACE Syndrome
For subjects in the large facial hemangioma arm of the study, a clinical assessment by trained physicians was conducted to determine whether or not each subject met diagnostic criteria for PHACE syndrome.
Spinal Abnormalities
The number of lumbrosacral hemangioma subjects with confirmed spinal abnormalities detected via lumbrosacral MRI.
Cerebrovascular and Structural Brain Abnormalities
The number of PHACE subjects identified with cerebrovascular and/or structural brain abnormalities detected using MRI.
Cardiac Abnormalities Detected Via Clinical Examination
The number of subjects with clinically definite PHACE syndrome who were identified as having cardiac abnormalities following clinical examination.
Frequency of Hepatic Hemangiomas Detected Via Abdominal Ultrasound
The number of participants with multiple (greater than or equal to 5) cutaneous infantile hemangiomas who were found to have hepatic hemangiomas via the us abdominal ultrasound.

Secondary Outcome Measures

Full Information

First Posted
November 1, 2006
Last Updated
September 17, 2013
Sponsor
Medical College of Wisconsin
Collaborators
University of California, San Francisco, Columbia University, Baylor College of Medicine, St. Justine's Hospital, State University of New York - Downstate Medical Center, Children's Mercy Hospital Kansas City, Children's Hospital Medical Center, Cincinnati, Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
search

1. Study Identification

Unique Protocol Identification Number
NCT00394888
Brief Title
Hemangioma Associated With High Rates of Morbidity
Official Title
Hemangioma Associated With High Rates of Morbidity:A Prospective Study
Study Type
Interventional

2. Study Status

Record Verification Date
September 2013
Overall Recruitment Status
Completed
Study Start Date
November 2005 (undefined)
Primary Completion Date
November 2009 (Actual)
Study Completion Date
January 2010 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Medical College of Wisconsin
Collaborators
University of California, San Francisco, Columbia University, Baylor College of Medicine, St. Justine's Hospital, State University of New York - Downstate Medical Center, Children's Mercy Hospital Kansas City, Children's Hospital Medical Center, Cincinnati, Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
We are conducting a study on the possible presence of PHACES in children with large facial hemangiomas and lumbosacral hemangiomas of infancy (hemangioma in the lower back) . With this study we hope to better understand the risk of this syndrome and to develop guidelines for its evaluation and management.
Detailed Description
Large hemangiomas of the face can be associated with anomalies of the blood vessels of head and chest. The acronym PHACES indicates the association of Posterior fossa and other brain malformations, facial Hemangioma, Arterial anomalies, Coarctation of the aorta and other cardiac defects, Eye abnormalities and Sternal malformations. Study subjects will be recruited through the Pediatric Dermatology department in several cities. All patients age 0-1 year old of age, who present with large facial hemangioma (>22 cm^2) will be offered to participate in the study. Parents will be interviewed to obtain personal, medical, and family history. Patients will undergo standard of care evaluation for facial hemangioma with risk of PHACE syndrome. This includes skin, eye and neurological examination, photograph, magnetic resonance imaging (MRI) of head/neck/chest, and lab tests requiring samples of blood, urine or stool. No other tests will be performed for participating in the study. Lumbosacral hemangiomas of infancy (hemangioma in the lower back) can be associated with anomalies of the spine. "Tethered cord syndrome" indicates a condition caused by abnormally stretched spinal cord. Over time this condition can lead to neurological damage. Although often there are no symptoms until adulthood, it can become apparent during childhood. Common symptoms are: lower back pain, pain and weakness of the legs, walking problems, and bladder and bowel loss of control. "Occult spinal dysraphism" is the term used when the defect of the spine is hidden under normal skin. We noticed that infants with hemangioma in the lower back area are more inclined to present a hidden spine defect. Study subjects will be recruited through the Pediatric Dermatology departments in several cities. All patients age 0-18 year old of age, who present with lumbosacral hemangioma (> 2.5 cm of diameter overlying the spine) will be offered to participate in the study. Parents will be interviewed to obtain personal, medical, and family history. Patients will undergo standard of care evaluation for lumbosacral hemangioma. This includes skin, neurological examination, photograph, magnetic resonance imaging (MRI) of the back, lab tests requiring samples of blood, urine or stool. No additional tests will be performed only for participating in the study.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hemangioma
Keywords
Hemangioma, PHACE, Lumbosacral hemangioma, Occult Spinal Dysraphism

7. Study Design

Primary Purpose
Screening
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
433 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Facial Hemangioma
Arm Type
Other
Arm Description
Patients with large facial hemangioma.
Arm Title
Lumbosacral Hemangioma
Arm Type
Other
Arm Description
Patients with lumbosacral hemangioma.
Arm Title
Multiple Hemangiomas
Arm Type
Other
Arm Description
patients with multiple hemangiomas (>5)
Intervention Type
Device
Intervention Name(s)
MRI
Intervention Description
MRI of the spine.
Intervention Type
Device
Intervention Name(s)
MRI of head and neck
Intervention Description
MRI of head and C-spine
Intervention Type
Other
Intervention Name(s)
Dermatological Examination
Other Intervention Name(s)
Clinical dermatological examination
Intervention Description
Complete dermatological examination to identify and characterize nature of dermatological anomalies
Intervention Type
Other
Intervention Name(s)
Cardiac examination
Other Intervention Name(s)
Cardiovascular examination
Intervention Description
Complete cardiac examination
Intervention Type
Device
Intervention Name(s)
Abdominal ultrasound
Intervention Description
Abdominal ultrasound to detect hepatic hemangiomas
Primary Outcome Measure Information:
Title
MRI/MRA of Head/Neck/Chest.
Time Frame
2 years
Title
Clinical Diagnosis of PHACE Syndrome
Description
For subjects in the large facial hemangioma arm of the study, a clinical assessment by trained physicians was conducted to determine whether or not each subject met diagnostic criteria for PHACE syndrome.
Time Frame
2 years
Title
Spinal Abnormalities
Description
The number of lumbrosacral hemangioma subjects with confirmed spinal abnormalities detected via lumbrosacral MRI.
Time Frame
2 years
Title
Cerebrovascular and Structural Brain Abnormalities
Description
The number of PHACE subjects identified with cerebrovascular and/or structural brain abnormalities detected using MRI.
Time Frame
2 years
Title
Cardiac Abnormalities Detected Via Clinical Examination
Description
The number of subjects with clinically definite PHACE syndrome who were identified as having cardiac abnormalities following clinical examination.
Time Frame
2 years
Title
Frequency of Hepatic Hemangiomas Detected Via Abdominal Ultrasound
Description
The number of participants with multiple (greater than or equal to 5) cutaneous infantile hemangiomas who were found to have hepatic hemangiomas via the us abdominal ultrasound.
Time Frame
2 years

10. Eligibility

Sex
All
Maximum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Segmental Facial Hemangioma Inclusion criteria: Infants less than 1 year of age Hemangiomas of the head /facial area measuring 22cm2 or greater. Exclusion criteria: Children greater than 1 year of age. Children with segmental hemangiomas present in locations other than the head. Children presenting with localized (focal) or indeterminate hemangiomas in any location. Children with other vascular tumors (such as tufted angioma, Kaposiform hemangioendothelioma, non-involuting congenital hemangioma or rapidly-involuting congenital hemangioma) or vascular malformations. Lumbosacral Hemangioma Inclusion criteria: Individuals less than 18 years of age. Hemangioma, hemangioma precursor, or definitive residual hemangioma larger then 2.5 cm in diameter, overlying the midline lumbar spine or sacral spine in which any portion of the hemangioma is located over the midline. Exclusion Criteria: Excluding perirectal hemangiomas that do not extend onto the sacral spine. Excluding perineal hemangiomas that do extend to overlay the sacral spine.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Beth Drolet, MD
Organizational Affiliation
Medical College of Wisconsin
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Maria Garzon, MD
Organizational Affiliation
Columbia University
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Denise Metry, MD
Organizational Affiliation
Baylor College of Medicine
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Ilona Frieden, MD
Organizational Affiliation
University of California, San Francisco
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Julie Powell, MD
Organizational Affiliation
Hopital Sainte-Justine
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Anne Lucky, MD
Organizational Affiliation
Children's Hospital of Cincinnati
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Sharon Glick, MD
Organizational Affiliation
State University of New York - Downstate Medical Center
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Eulalia Baselga, MD
Organizational Affiliation
Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Anita Haggstrom, M.D.
Organizational Affiliation
Indiana University
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Anthony Mancini, MD
Organizational Affiliation
Northwestern University
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Kimberly Horii, MD
Organizational Affiliation
Children's Mercy Hospital Kansas City
Official's Role
Principal Investigator
Facility Information:
Facility Name
Beth Drolet, MD
City
Milwaukee
State/Province
Wisconsin
ZIP/Postal Code
53226
Country
United States

12. IPD Sharing Statement

Learn more about this trial

Hemangioma Associated With High Rates of Morbidity

We'll reach out to this number within 24 hrs